Elahere Shortage Update: What Patients Need to Know in 2026

If you or a loved one relies on Elahere (mirvetuximab soravtansine-gynx) for platinum-resistant ovarian cancer, you may have heard worries about drug availability. Here is the most current information on Elahere's supply status in 2026 and what it means for patients.

Is Elahere Currently in Shortage?

As of 2026, Elahere is not listed on the FDA Drug Shortage Database. Elahere is manufactured by AbbVie (which acquired ImmunoGen, the original developer, in February 2024) and is produced under controlled manufacturing conditions as a specialty biologic. There have been no public reports of manufacturing disruptions or supply chain failures affecting Elahere's availability.

However, "no formal shortage" does not mean every patient can easily access Elahere. Access barriers are real, widespread, and can feel just as frustrating as a supply shortage to affected patients.

What's Causing Access Difficulties in 2026?

The access challenges patients face with Elahere in 2026 are structural, not supply-related:

Companion diagnostic requirement: Patients must first be confirmed FRα-positive via the VENTANA FOLR1 (FOLR-2.1) RxDx Assay. This testing must be arranged and completed before treatment can begin.

Insurance prior authorization: At ~$29,307 per treatment cycle, Elahere requires prior authorization from most insurance plans. The process can take 2-4 weeks or longer.

Specialty distribution: Elahere flows through specialty pharmacies to oncology infusion centers — not standard retail channels. Patients must receive treatment at a properly equipped facility.

Geographic disparities: Patients in rural areas or regions without major cancer centers may face longer travel times to reach facilities that administer Elahere.

Background: How Did Elahere Get Here?

Elahere was developed by ImmunoGen as a first-in-class antibody-drug conjugate targeting folate receptor alpha (FRα). The FDA granted accelerated approval in November 2022 based on the SORAYA trial, which showed a 31.7% objective response rate in platinum-resistant ovarian cancer. Following the Phase 3 MIRASOL trial — which showed Elahere improved overall survival by 3.8 months (16.5 vs 12.7 months) and reduced the risk of death by 33% compared to standard chemotherapy — the FDA granted full approval on March 22, 2024.

AbbVie acquired ImmunoGen in February 2024, adding Elahere to its portfolio and significantly expanding the commercial infrastructure supporting the drug. Since the AbbVie acquisition, the supply chain and patient support infrastructure around Elahere have expanded.

Will There Be an Elahere Shortage in the Future?

Supply shortages of specialty biologics are always possible and can be caused by manufacturing issues, raw material shortages, unexpected demand surges, or distribution problems. However, as of 2026, there are no credible signals pointing to an imminent Elahere shortage. AbbVie is a large pharmaceutical company with robust manufacturing capabilities, and Elahere is a high-priority commercial product.

If a shortage does occur, the FDA's Drug Shortage Staff would work with AbbVie to resolve it. The FDA Drug Shortage Database (drugshortages.fda.gov) is the authoritative source for up-to-date information — check it if you're concerned.

What Should You Do If You Can't Get Elahere Right Now?

Contact ELAHERE Support Services immediately: 1-833-ELAHERE (1-833-352-4373). Their Case Managers specialize in navigating insurance and access barriers.

Ask your oncologist to appeal an insurance denial if prior authorization was rejected — providing clinical evidence from the MIRASOL trial often helps.

Explore the AbbVie Patient Assistance Program (myAbbVie Assist) if you lack insurance or your insurance doesn't cover Elahere.

Ask about bridging therapy if there's a delay — your oncologist may recommend a temporary chemotherapy regimen while insurance approval is pending.

How medfinder Helps Patients Find Elahere

If you're struggling to find an infusion center that administers Elahere, medfinder is a paid service that calls facilities near you to identify which ones can fill your Elahere prescription. Elahere requires IV administration at a qualified oncology center — and medfinder can save you the exhausting work of calling every cancer center in your area.

If access delays force you to consider other options, see our guide on Alternatives to Elahere If You Can't Fill Your Prescription.